View of Clinical outcomes of neoadjuvant dual HER2 blockade with pertuzumab/Sigrima and trastuzumab/Vivitra biosimilars: real-world evidence in HER2-positive breast cancer in India

Return to Article Details Clinical outcomes of neoadjuvant dual HER2 blockade with pertuzumab/Sigrima and trastuzumab/Vivitra biosimilars: real-world evidence in HER2-positive breast cancer in India Download Download PDF